| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 75 | 2025 | 628 | 19.120 |
Why?
|
| Mucin-5B | 47 | 2025 | 218 | 13.040 |
Why?
|
| Pulmonary Fibrosis | 53 | 2025 | 378 | 8.180 |
Why?
|
| Lipopolysaccharides | 58 | 2013 | 856 | 6.330 |
Why?
|
| Lung | 94 | 2025 | 3752 | 5.670 |
Why?
|
| Genetic Predisposition to Disease | 70 | 2024 | 2267 | 5.120 |
Why?
|
| Pregnancy Complications, Infectious | 10 | 2024 | 364 | 4.970 |
Why?
|
| Lung Diseases, Interstitial | 31 | 2025 | 597 | 4.330 |
Why?
|
| Asthma | 41 | 2023 | 2219 | 3.450 |
Why?
|
| Polymorphism, Genetic | 31 | 2022 | 639 | 3.420 |
Why?
|
| Immunity, Innate | 30 | 2019 | 805 | 3.360 |
Why?
|
| Toll-Like Receptor 4 | 37 | 2014 | 263 | 3.110 |
Why?
|
| Epigenesis, Genetic | 19 | 2022 | 616 | 3.020 |
Why?
|
| Respiratory Mucosa | 19 | 2025 | 306 | 2.920 |
Why?
|
| Infectious Disease Transmission, Vertical | 9 | 2024 | 170 | 2.910 |
Why?
|
| Environmental Exposure | 18 | 2019 | 464 | 2.900 |
Why?
|
| Membrane Glycoproteins | 20 | 2010 | 466 | 2.860 |
Why?
|
| Pandemics | 12 | 2024 | 1491 | 2.810 |
Why?
|
| Receptors, Cell Surface | 19 | 2015 | 371 | 2.780 |
Why?
|
| Genome-Wide Association Study | 33 | 2024 | 1337 | 2.760 |
Why?
|
| Dust | 23 | 2018 | 99 | 2.720 |
Why?
|
| Lung Diseases | 19 | 2018 | 723 | 2.670 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 338 | 2.550 |
Why?
|
| Promoter Regions, Genetic | 25 | 2022 | 1200 | 2.510 |
Why?
|
| DNA Methylation | 18 | 2022 | 605 | 2.460 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 342 | 2.440 |
Why?
|
| Bleomycin | 12 | 2023 | 240 | 2.350 |
Why?
|
| Genetic Variation | 18 | 2022 | 934 | 2.330 |
Why?
|
| Polymorphism, Single Nucleotide | 35 | 2024 | 2065 | 2.210 |
Why?
|
| Humans | 312 | 2025 | 129116 | 2.180 |
Why?
|
| Endotoxins | 20 | 2013 | 216 | 2.170 |
Why?
|
| Bronchoalveolar Lavage Fluid | 49 | 2022 | 627 | 2.160 |
Why?
|
| Alveolitis, Extrinsic Allergic | 3 | 2022 | 92 | 2.130 |
Why?
|
| Mice | 109 | 2023 | 16644 | 2.000 |
Why?
|
| Genomics | 13 | 2024 | 716 | 1.960 |
Why?
|
| Bronchial Hyperreactivity | 19 | 2015 | 104 | 1.930 |
Why?
|
| Drosophila Proteins | 12 | 2002 | 187 | 1.870 |
Why?
|
| Animals | 142 | 2025 | 34600 | 1.860 |
Why?
|
| Respiratory Tract Diseases | 12 | 2010 | 150 | 1.830 |
Why?
|
| Crohn Disease | 8 | 2024 | 211 | 1.800 |
Why?
|
| Pneumonia | 17 | 2012 | 599 | 1.760 |
Why?
|
| Toll-Like Receptors | 23 | 2018 | 179 | 1.730 |
Why?
|
| Zea mays | 13 | 2001 | 41 | 1.690 |
Why?
|
| Gene Expression | 23 | 2022 | 1462 | 1.670 |
Why?
|
| Gene Expression Regulation | 24 | 2024 | 2508 | 1.640 |
Why?
|
| Male | 196 | 2025 | 63194 | 1.620 |
Why?
|
| Gene Expression Profiling | 25 | 2024 | 1689 | 1.600 |
Why?
|
| Female | 172 | 2025 | 68510 | 1.580 |
Why?
|
| Placenta | 7 | 2024 | 716 | 1.570 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2020 | 13 | 1.550 |
Why?
|
| Betacoronavirus | 5 | 2020 | 252 | 1.530 |
Why?
|
| Transcriptome | 12 | 2024 | 883 | 1.480 |
Why?
|
| Middle Aged | 123 | 2025 | 31074 | 1.440 |
Why?
|
| Interleukin-6 | 12 | 2022 | 718 | 1.440 |
Why?
|
| Genotype | 23 | 2025 | 1832 | 1.410 |
Why?
|
| Phenotype | 29 | 2025 | 3058 | 1.410 |
Why?
|
| Cytokines | 32 | 2024 | 1987 | 1.350 |
Why?
|
| Quantitative Trait Loci | 9 | 2022 | 356 | 1.340 |
Why?
|
| Rectal Fistula | 2 | 2021 | 21 | 1.320 |
Why?
|
| Mice, Inbred C57BL | 50 | 2022 | 5284 | 1.290 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 12 | 2019 | 953 | 1.290 |
Why?
|
| Case-Control Studies | 30 | 2022 | 3342 | 1.270 |
Why?
|
| Allergens | 12 | 2024 | 383 | 1.220 |
Why?
|
| Genetic Loci | 9 | 2022 | 274 | 1.220 |
Why?
|
| Aged | 77 | 2025 | 22083 | 1.190 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 4 | 2019 | 44 | 1.180 |
Why?
|
| Gain of Function Mutation | 4 | 2022 | 33 | 1.170 |
Why?
|
| Respiratory Hypersensitivity | 6 | 2018 | 65 | 1.160 |
Why?
|
| Mucociliary Clearance | 2 | 2018 | 42 | 1.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 27 | 2024 | 1192 | 1.130 |
Why?
|
| Biomarkers | 14 | 2025 | 3896 | 1.120 |
Why?
|
| Administration, Inhalation | 27 | 2013 | 664 | 1.120 |
Why?
|
| Hypersensitivity | 7 | 2024 | 250 | 1.090 |
Why?
|
| Stillbirth | 3 | 2022 | 61 | 1.090 |
Why?
|
| Precision Medicine | 6 | 2024 | 384 | 1.090 |
Why?
|
| Signal Transduction | 27 | 2022 | 4838 | 1.060 |
Why?
|
| Adult | 98 | 2025 | 35510 | 1.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 18 | 2016 | 757 | 1.020 |
Why?
|
| Pulmonary Alveoli | 7 | 2025 | 366 | 1.010 |
Why?
|
| Disease Models, Animal | 29 | 2023 | 3953 | 1.010 |
Why?
|
| Pregnancy | 20 | 2024 | 6375 | 1.000 |
Why?
|
| RNA | 9 | 2022 | 883 | 1.000 |
Why?
|
| Risk Factors | 37 | 2024 | 9767 | 0.980 |
Why?
|
| Epithelium | 4 | 2022 | 306 | 0.970 |
Why?
|
| Skin Tests | 3 | 2024 | 100 | 0.970 |
Why?
|
| Smoking | 27 | 2022 | 1466 | 0.950 |
Why?
|
| Neutrophils | 24 | 2012 | 1195 | 0.950 |
Why?
|
| Acetone | 1 | 2024 | 12 | 0.940 |
Why?
|
| Infant, Newborn | 15 | 2024 | 5739 | 0.920 |
Why?
|
| Mucus | 4 | 2019 | 75 | 0.910 |
Why?
|
| Lung Transplantation | 6 | 2017 | 276 | 0.910 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2023 | 26 | 0.880 |
Why?
|
| Macrophages | 15 | 2016 | 1466 | 0.860 |
Why?
|
| Asbestos | 9 | 2012 | 28 | 0.860 |
Why?
|
| Blood Proteins | 3 | 2025 | 240 | 0.850 |
Why?
|
| RNA, Messenger | 20 | 2021 | 2676 | 0.850 |
Why?
|
| Genome, Human | 6 | 2021 | 392 | 0.850 |
Why?
|
| Inhalation Exposure | 5 | 2012 | 91 | 0.840 |
Why?
|
| Coronavirus | 2 | 2020 | 43 | 0.840 |
Why?
|
| Early Diagnosis | 3 | 2022 | 236 | 0.840 |
Why?
|
| Graft Rejection | 5 | 2007 | 558 | 0.830 |
Why?
|
| Occupational Exposure | 10 | 2018 | 311 | 0.820 |
Why?
|
| Occupational Diseases | 10 | 2008 | 141 | 0.810 |
Why?
|
| Caenorhabditis elegans | 5 | 2013 | 291 | 0.810 |
Why?
|
| Saccharopolyspora | 1 | 2022 | 6 | 0.810 |
Why?
|
| Edible Grain | 8 | 2003 | 48 | 0.800 |
Why?
|
| Perinatal Death | 1 | 2022 | 22 | 0.790 |
Why?
|
| Sequence Analysis, DNA | 9 | 2023 | 773 | 0.790 |
Why?
|
| Mice, Inbred Strains | 15 | 2016 | 402 | 0.790 |
Why?
|
| Mutation | 16 | 2022 | 3700 | 0.760 |
Why?
|
| Respiratory System | 7 | 2022 | 153 | 0.750 |
Why?
|
| Inflammation | 27 | 2024 | 2668 | 0.750 |
Why?
|
| Maternal Exposure | 4 | 2020 | 175 | 0.740 |
Why?
|
| Integrins | 1 | 2022 | 92 | 0.740 |
Why?
|
| Cellular Senescence | 2 | 2021 | 174 | 0.740 |
Why?
|
| Placenta Diseases | 1 | 2021 | 14 | 0.740 |
Why?
|
| Airway Obstruction | 6 | 2000 | 149 | 0.730 |
Why?
|
| Chorionic Villi | 1 | 2021 | 22 | 0.730 |
Why?
|
| Epithelial Cells | 6 | 2024 | 1036 | 0.720 |
Why?
|
| Mice, Inbred C3H | 16 | 2010 | 274 | 0.720 |
Why?
|
| Receptors, Immunologic | 3 | 2015 | 209 | 0.710 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2019 | 56 | 0.710 |
Why?
|
| Ozone | 6 | 2012 | 103 | 0.710 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2021 | 99 | 0.710 |
Why?
|
| Placental Insufficiency | 1 | 2022 | 111 | 0.710 |
Why?
|
| Mice, Knockout | 21 | 2019 | 2765 | 0.700 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 4 | 2019 | 35 | 0.700 |
Why?
|
| Pregnancy Outcome | 2 | 2020 | 389 | 0.700 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 25 | 0.690 |
Why?
|
| Respiratory Function Tests | 17 | 2021 | 583 | 0.680 |
Why?
|
| Nasal Mucosa | 3 | 2017 | 107 | 0.660 |
Why?
|
| Fibrosis | 9 | 2023 | 522 | 0.660 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 1 | 2019 | 9 | 0.660 |
Why?
|
| Risk Assessment | 12 | 2020 | 3260 | 0.650 |
Why?
|
| Macrophages, Alveolar | 10 | 2009 | 380 | 0.640 |
Why?
|
| Aspartic Acid | 2 | 2014 | 80 | 0.640 |
Why?
|
| Cysts | 2 | 2019 | 108 | 0.640 |
Why?
|
| Trophoblasts | 1 | 2021 | 190 | 0.630 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 178 | 0.630 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2019 | 68 | 0.630 |
Why?
|
| Career Choice | 1 | 2021 | 211 | 0.620 |
Why?
|
| Metagenomics | 2 | 2011 | 154 | 0.620 |
Why?
|
| Alpha-Globulins | 3 | 2009 | 20 | 0.610 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2021 | 25 | 0.610 |
Why?
|
| Physicians | 2 | 2021 | 861 | 0.610 |
Why?
|
| Lung Injury | 4 | 2021 | 199 | 0.610 |
Why?
|
| Glycine | 2 | 2014 | 165 | 0.600 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2018 | 563 | 0.600 |
Why?
|
| Tomography, X-Ray Computed | 21 | 2025 | 2541 | 0.600 |
Why?
|
| Paraquat | 1 | 2018 | 15 | 0.590 |
Why?
|
| Cohort Studies | 21 | 2025 | 5407 | 0.590 |
Why?
|
| Herbicides | 1 | 2018 | 22 | 0.580 |
Why?
|
| Lipopolysaccharide Receptors | 4 | 2007 | 88 | 0.580 |
Why?
|
| Disease | 3 | 2011 | 94 | 0.580 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2018 | 34 | 0.580 |
Why?
|
| Telomere | 6 | 2024 | 226 | 0.570 |
Why?
|
| Escherichia coli | 14 | 2011 | 771 | 0.560 |
Why?
|
| Animal Husbandry | 6 | 2021 | 38 | 0.550 |
Why?
|
| Neutrophil Infiltration | 4 | 2012 | 103 | 0.550 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2021 | 312 | 0.550 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 764 | 0.550 |
Why?
|
| Vital Capacity | 18 | 2015 | 291 | 0.550 |
Why?
|
| Air Pollutants, Occupational | 4 | 2009 | 36 | 0.540 |
Why?
|
| Complement C3 | 1 | 2018 | 198 | 0.540 |
Why?
|
| Shock, Septic | 4 | 2011 | 206 | 0.540 |
Why?
|
| Interferon-gamma | 7 | 2007 | 762 | 0.540 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 127 | 0.540 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 439 | 0.540 |
Why?
|
| Bronchioles | 1 | 2016 | 22 | 0.530 |
Why?
|
| Alleles | 9 | 2017 | 845 | 0.530 |
Why?
|
| Desmoplakins | 1 | 2016 | 19 | 0.520 |
Why?
|
| Methamphetamine | 1 | 2017 | 56 | 0.520 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2018 | 89 | 0.520 |
Why?
|
| Aged, 80 and over | 20 | 2024 | 7064 | 0.520 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 61 | 0.520 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 348 | 0.510 |
Why?
|
| CpG Islands | 5 | 2020 | 152 | 0.510 |
Why?
|
| Fibroblasts | 6 | 2025 | 939 | 0.510 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 108 | 0.500 |
Why?
|
| Sequence Analysis, RNA | 3 | 2019 | 428 | 0.500 |
Why?
|
| China | 3 | 2020 | 191 | 0.490 |
Why?
|
| Scleroderma, Systemic | 2 | 2013 | 104 | 0.480 |
Why?
|
| Urban Population | 3 | 2015 | 444 | 0.480 |
Why?
|
| Idiopathic Interstitial Pneumonias | 4 | 2019 | 49 | 0.480 |
Why?
|
| Young Adult | 18 | 2024 | 12389 | 0.480 |
Why?
|
| Bronchial Provocation Tests | 8 | 2011 | 50 | 0.470 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2022 | 1109 | 0.460 |
Why?
|
| Biomedical Research | 4 | 2024 | 647 | 0.460 |
Why?
|
| Polymerase Chain Reaction | 12 | 2016 | 1021 | 0.460 |
Why?
|
| United States | 27 | 2025 | 13938 | 0.460 |
Why?
|
| GTPase-Activating Proteins | 4 | 2023 | 81 | 0.460 |
Why?
|
| Th2 Cells | 4 | 2012 | 167 | 0.450 |
Why?
|
| Health Care Costs | 1 | 2017 | 395 | 0.450 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2018 | 43 | 0.450 |
Why?
|
| Cilia | 3 | 2022 | 179 | 0.450 |
Why?
|
| Immunoglobulin E | 8 | 2015 | 329 | 0.440 |
Why?
|
| Inhalation | 3 | 2008 | 28 | 0.440 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2003 | 133 | 0.440 |
Why?
|
| Forced Expiratory Volume | 18 | 2015 | 511 | 0.440 |
Why?
|
| Clinical Competence | 1 | 2021 | 1021 | 0.440 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 538 | 0.430 |
Why?
|
| Environment | 2 | 2006 | 347 | 0.430 |
Why?
|
| Chromosomes, Mammalian | 2 | 2011 | 26 | 0.430 |
Why?
|
| Colonic Pouches | 3 | 2021 | 14 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2013 | 21 | 0.420 |
Why?
|
| Retrospective Studies | 13 | 2024 | 14571 | 0.420 |
Why?
|
| Interleukin-10 | 4 | 2006 | 299 | 0.420 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 6 | 2024 | 101 | 0.420 |
Why?
|
| Gastrointestinal Agents | 3 | 2021 | 60 | 0.410 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 230 | 0.410 |
Why?
|
| Immune Tolerance | 3 | 2013 | 349 | 0.410 |
Why?
|
| Whole Genome Sequencing | 3 | 2023 | 131 | 0.410 |
Why?
|
| Diffusion of Innovation | 2 | 2018 | 96 | 0.410 |
Why?
|
| Sarcoidosis | 3 | 2013 | 155 | 0.400 |
Why?
|
| PPAR gamma | 1 | 2013 | 182 | 0.400 |
Why?
|
| Hyaluronic Acid | 3 | 2009 | 212 | 0.400 |
Why?
|
| Respiratory Mechanics | 4 | 1994 | 64 | 0.400 |
Why?
|
| Telomere Homeostasis | 3 | 2024 | 28 | 0.400 |
Why?
|
| Health Status | 4 | 2011 | 751 | 0.390 |
Why?
|
| Asbestosis | 9 | 1994 | 13 | 0.390 |
Why?
|
| Hypoxia | 2 | 2022 | 1035 | 0.380 |
Why?
|
| Lipid A | 2 | 2005 | 29 | 0.380 |
Why?
|
| Pouchitis | 2 | 2021 | 5 | 0.380 |
Why?
|
| Colitis, Ulcerative | 3 | 2021 | 114 | 0.380 |
Why?
|
| RNA Interference | 8 | 2016 | 441 | 0.380 |
Why?
|
| DNA | 4 | 2022 | 1392 | 0.380 |
Why?
|
| Science | 1 | 2012 | 52 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 767 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2011 | 57 | 0.360 |
Why?
|
| Species Specificity | 8 | 2015 | 570 | 0.360 |
Why?
|
| Chronic Disease | 9 | 2021 | 1706 | 0.360 |
Why?
|
| Agricultural Workers' Diseases | 3 | 1996 | 33 | 0.350 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2006 | 125 | 0.350 |
Why?
|
| Pulmonary Emphysema | 2 | 2015 | 244 | 0.350 |
Why?
|
| Methacholine Chloride | 10 | 2015 | 51 | 0.340 |
Why?
|
| Air Pollutants | 4 | 2013 | 312 | 0.340 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2020 | 378 | 0.340 |
Why?
|
| Mucin 5AC | 4 | 2015 | 69 | 0.340 |
Why?
|
| Disease Progression | 12 | 2021 | 2613 | 0.340 |
Why?
|
| Fucosyltransferases | 2 | 2022 | 32 | 0.340 |
Why?
|
| Medicine | 1 | 2012 | 117 | 0.340 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 410 | 0.340 |
Why?
|
| Bone Marrow Transplantation | 3 | 2009 | 268 | 0.340 |
Why?
|
| Enterobacteriaceae | 4 | 2013 | 35 | 0.340 |
Why?
|
| Lung Diseases, Obstructive | 3 | 2001 | 44 | 0.340 |
Why?
|
| Hyaluronan Receptors | 3 | 2009 | 97 | 0.340 |
Why?
|
| Toll-Like Receptor 2 | 6 | 2013 | 110 | 0.330 |
Why?
|
| Cell Line | 11 | 2021 | 2737 | 0.330 |
Why?
|
| Disease Susceptibility | 3 | 2013 | 335 | 0.330 |
Why?
|
| Persian Gulf Syndrome | 4 | 2004 | 12 | 0.330 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 2079 | 0.330 |
Why?
|
| Receptors, Interleukin-1 Type I | 2 | 2007 | 24 | 0.320 |
Why?
|
| Germ Cells | 1 | 2009 | 59 | 0.320 |
Why?
|
| Prevalence | 13 | 2022 | 2564 | 0.320 |
Why?
|
| Pleural Diseases | 4 | 1993 | 17 | 0.310 |
Why?
|
| Karyotyping | 1 | 2008 | 107 | 0.310 |
Why?
|
| Caenorhabditis elegans Proteins | 4 | 2013 | 191 | 0.310 |
Why?
|
| Immunohistochemistry | 7 | 2015 | 1671 | 0.310 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 491 | 0.310 |
Why?
|
| Chromosome Mapping | 6 | 2011 | 505 | 0.310 |
Why?
|
| Housing, Animal | 1 | 2009 | 47 | 0.310 |
Why?
|
| Interleukin-1 | 8 | 2003 | 961 | 0.310 |
Why?
|
| Flour | 1 | 2008 | 6 | 0.310 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2020 | 431 | 0.300 |
Why?
|
| Hospitalization | 4 | 2025 | 2077 | 0.300 |
Why?
|
| Lung Diseases, Fungal | 1 | 2008 | 12 | 0.300 |
Why?
|
| Longevity | 1 | 2009 | 149 | 0.300 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 25 | 0.300 |
Why?
|
| Aspergillosis | 1 | 2008 | 21 | 0.300 |
Why?
|
| Prospective Studies | 22 | 2025 | 7079 | 0.300 |
Why?
|
| Plasminogen | 1 | 2008 | 31 | 0.300 |
Why?
|
| Adolescent | 25 | 2024 | 20301 | 0.300 |
Why?
|
| Base Sequence | 7 | 2017 | 2135 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2019 | 1945 | 0.300 |
Why?
|
| Total Lung Capacity | 9 | 2015 | 33 | 0.300 |
Why?
|
| Mice, Inbred BALB C | 8 | 2015 | 1230 | 0.300 |
Why?
|
| DNA, Bacterial | 3 | 2014 | 324 | 0.300 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2006 | 65 | 0.300 |
Why?
|
| Genes | 2 | 2006 | 226 | 0.300 |
Why?
|
| Ovalbumin | 8 | 2015 | 177 | 0.290 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 471 | 0.290 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 543 | 0.290 |
Why?
|
| Transplantation Immunology | 2 | 2005 | 33 | 0.290 |
Why?
|
| Bronchi | 5 | 2005 | 240 | 0.290 |
Why?
|
| Gene Frequency | 7 | 2023 | 504 | 0.290 |
Why?
|
| Airway Resistance | 4 | 2011 | 38 | 0.290 |
Why?
|
| Genetic Markers | 5 | 2022 | 339 | 0.290 |
Why?
|
| Complement Inactivator Proteins | 1 | 2007 | 40 | 0.280 |
Why?
|
| Graft Survival | 3 | 2007 | 505 | 0.280 |
Why?
|
| Otitis Media | 3 | 2019 | 160 | 0.280 |
Why?
|
| Streptococcus | 1 | 2007 | 25 | 0.280 |
Why?
|
| Complement System Proteins | 2 | 2007 | 307 | 0.280 |
Why?
|
| Leukocyte Count | 7 | 2009 | 328 | 0.280 |
Why?
|
| Bronchoconstriction | 4 | 2011 | 32 | 0.280 |
Why?
|
| Dyspnea | 6 | 2023 | 239 | 0.280 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2020 | 217 | 0.270 |
Why?
|
| Telomerase | 2 | 2019 | 231 | 0.270 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 90 | 0.270 |
Why?
|
| Mutation, Missense | 4 | 2002 | 318 | 0.270 |
Why?
|
| Cyclophosphamide | 3 | 2024 | 232 | 0.270 |
Why?
|
| Leukocytes | 3 | 2006 | 303 | 0.270 |
Why?
|
| Age Factors | 10 | 2019 | 3120 | 0.270 |
Why?
|
| Fetus | 3 | 2021 | 760 | 0.270 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 1496 | 0.270 |
Why?
|
| Logistic Models | 8 | 2019 | 1979 | 0.260 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 291 | 0.260 |
Why?
|
| Prednisone | 3 | 2024 | 236 | 0.260 |
Why?
|
| Constriction, Pathologic | 4 | 2021 | 229 | 0.260 |
Why?
|
| Toxicology | 1 | 2006 | 42 | 0.260 |
Why?
|
| Sepsis | 3 | 2010 | 557 | 0.250 |
Why?
|
| Arteriosclerosis | 2 | 2004 | 88 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 816 | 0.250 |
Why?
|
| Receptors, CCR5 | 1 | 2006 | 58 | 0.250 |
Why?
|
| DNA Helicases | 2 | 2019 | 149 | 0.250 |
Why?
|
| Transforming Growth Factor beta1 | 6 | 2007 | 155 | 0.250 |
Why?
|
| Hyperoxia | 1 | 2006 | 87 | 0.250 |
Why?
|
| Survival Analysis | 5 | 2015 | 1265 | 0.250 |
Why?
|
| Tobacco Use | 2 | 2023 | 61 | 0.250 |
Why?
|
| Child | 15 | 2022 | 20805 | 0.240 |
Why?
|
| Streptococcal Infections | 1 | 2007 | 145 | 0.240 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 4915 | 0.240 |
Why?
|
| Complement Activation | 2 | 2007 | 365 | 0.240 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 485 | 0.240 |
Why?
|
| Ligands | 3 | 2022 | 614 | 0.240 |
Why?
|
| Colorado | 3 | 2020 | 4394 | 0.240 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 690 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 6 | 2021 | 1671 | 0.240 |
Why?
|
| Organizational Objectives | 1 | 2005 | 70 | 0.240 |
Why?
|
| Mice, Inbred DBA | 4 | 2008 | 186 | 0.240 |
Why?
|
| Environmental Health | 1 | 2005 | 37 | 0.240 |
Why?
|
| Public Health | 1 | 2010 | 486 | 0.240 |
Why?
|
| Mothers | 2 | 2022 | 729 | 0.240 |
Why?
|
| Inflammation Mediators | 5 | 2019 | 500 | 0.240 |
Why?
|
| Linkage Disequilibrium | 3 | 2016 | 256 | 0.240 |
Why?
|
| Infant | 8 | 2022 | 8992 | 0.240 |
Why?
|
| Dual Oxidases | 1 | 2024 | 2 | 0.230 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2021 | 19 | 0.230 |
Why?
|
| Gram-Negative Bacteria | 3 | 2018 | 69 | 0.230 |
Why?
|
| Spirometry | 8 | 2015 | 251 | 0.230 |
Why?
|
| Congresses as Topic | 3 | 2018 | 215 | 0.230 |
Why?
|
| ErbB Receptors | 2 | 2021 | 603 | 0.230 |
Why?
|
| Acute-Phase Proteins | 1 | 2004 | 67 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2020 | 634 | 0.230 |
Why?
|
| Culture Media | 4 | 2018 | 167 | 0.230 |
Why?
|
| Exome | 2 | 2023 | 220 | 0.230 |
Why?
|
| Environmental Illness | 1 | 2004 | 2 | 0.230 |
Why?
|
| Dietary Supplements | 1 | 2008 | 532 | 0.230 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2005 | 119 | 0.230 |
Why?
|
| Extracellular Matrix | 3 | 2014 | 498 | 0.230 |
Why?
|
| Pleura | 3 | 1994 | 22 | 0.220 |
Why?
|
| Lipocalin-2 | 1 | 2024 | 76 | 0.220 |
Why?
|
| Cell Movement | 2 | 2007 | 939 | 0.220 |
Why?
|
| Vincristine | 1 | 2024 | 110 | 0.220 |
Why?
|
| Interleukin-8 | 7 | 2009 | 258 | 0.220 |
Why?
|
| Epigenomics | 2 | 2017 | 111 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 49 | 0.220 |
Why?
|
| Ileum | 1 | 2024 | 115 | 0.220 |
Why?
|
| Interleukin-13 | 4 | 2019 | 145 | 0.220 |
Why?
|
| Genetic Linkage | 3 | 2011 | 299 | 0.220 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 109 | 0.220 |
Why?
|
| Dogs | 1 | 2024 | 366 | 0.220 |
Why?
|
| Chagas Cardiomyopathy | 2 | 2015 | 21 | 0.210 |
Why?
|
| Rituximab | 1 | 2024 | 163 | 0.210 |
Why?
|
| Enterobacteriaceae Infections | 3 | 2013 | 36 | 0.210 |
Why?
|
| Transcription, Genetic | 4 | 2013 | 1403 | 0.210 |
Why?
|
| Acute Disease | 6 | 2021 | 968 | 0.210 |
Why?
|
| Regression Analysis | 5 | 2017 | 984 | 0.210 |
Why?
|
| Alveolar Epithelial Cells | 3 | 2019 | 97 | 0.210 |
Why?
|
| Eukaryotic Initiation Factor-2B | 1 | 2023 | 6 | 0.210 |
Why?
|
| Treatment Outcome | 8 | 2024 | 10226 | 0.210 |
Why?
|
| Drug Repositioning | 1 | 2023 | 25 | 0.210 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 1210 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 113 | 0.210 |
Why?
|
| Transcription Factors | 4 | 2021 | 1632 | 0.210 |
Why?
|
| Bacteroides fragilis | 1 | 2002 | 12 | 0.200 |
Why?
|
| Time Factors | 15 | 2018 | 6518 | 0.200 |
Why?
|
| Mucins | 3 | 2019 | 70 | 0.200 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2008 | 44 | 0.200 |
Why?
|
| Doxorubicin | 1 | 2024 | 322 | 0.200 |
Why?
|
| Dermatitis, Atopic | 2 | 2022 | 321 | 0.200 |
Why?
|
| Pedigree | 7 | 2019 | 486 | 0.200 |
Why?
|
| ROC Curve | 3 | 2019 | 502 | 0.200 |
Why?
|
| Silicosis | 1 | 2023 | 27 | 0.200 |
Why?
|
| CD11b Antigen | 1 | 2002 | 59 | 0.200 |
Why?
|
| Obstetric Labor, Premature | 1 | 2002 | 35 | 0.200 |
Why?
|
| Histones | 2 | 2022 | 584 | 0.200 |
Why?
|
| Gene Regulatory Networks | 2 | 2016 | 281 | 0.200 |
Why?
|
| Double-Blind Method | 5 | 2021 | 1865 | 0.200 |
Why?
|
| Colon | 1 | 2024 | 251 | 0.200 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2023 | 101 | 0.200 |
Why?
|
| DNA Mutational Analysis | 6 | 2017 | 386 | 0.200 |
Why?
|
| Bacterial Infections | 6 | 2013 | 229 | 0.200 |
Why?
|
| Chemokine CXCL2 | 5 | 2001 | 43 | 0.200 |
Why?
|
| Blotting, Western | 4 | 2013 | 1169 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 391 | 0.190 |
Why?
|
| Endoscopy | 2 | 2021 | 268 | 0.190 |
Why?
|
| Fibrinolysis | 1 | 2003 | 133 | 0.190 |
Why?
|
| Internationality | 1 | 2022 | 148 | 0.190 |
Why?
|
| A549 Cells | 2 | 2021 | 58 | 0.190 |
Why?
|
| Fetal Death | 1 | 2022 | 56 | 0.190 |
Why?
|
| Peptide Hydrolases | 1 | 2022 | 106 | 0.190 |
Why?
|
| Monokines | 5 | 2000 | 22 | 0.190 |
Why?
|
| Fibrin | 1 | 2022 | 68 | 0.190 |
Why?
|
| Tyrphostins | 1 | 2021 | 17 | 0.190 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 73 | 0.190 |
Why?
|
| Amphiregulin | 1 | 2021 | 25 | 0.190 |
Why?
|
| Immunity | 1 | 2022 | 132 | 0.190 |
Why?
|
| Carbapenems | 2 | 2011 | 16 | 0.190 |
Why?
|
| E2F1 Transcription Factor | 2 | 2012 | 61 | 0.190 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 149 | 0.190 |
Why?
|
| Biophysical Phenomena | 1 | 2021 | 64 | 0.190 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2021 | 33 | 0.190 |
Why?
|
| Eosinophils | 5 | 2015 | 324 | 0.180 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2022 | 50 | 0.180 |
Why?
|
| Receptors, Interleukin-1 | 4 | 2010 | 223 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2018 | 336 | 0.180 |
Why?
|
| Telemedicine | 2 | 2021 | 783 | 0.180 |
Why?
|
| Proteome | 2 | 2017 | 431 | 0.180 |
Why?
|
| Keratin-5 | 1 | 2021 | 49 | 0.180 |
Why?
|
| Bacteremia | 2 | 2013 | 194 | 0.180 |
Why?
|
| Office Visits | 1 | 2021 | 81 | 0.180 |
Why?
|
| Tennessee | 1 | 2020 | 42 | 0.180 |
Why?
|
| Phagocytosis | 3 | 2013 | 364 | 0.180 |
Why?
|
| Colectomy | 1 | 2021 | 94 | 0.180 |
Why?
|
| Cell Communication | 1 | 2022 | 299 | 0.180 |
Why?
|
| Swine | 5 | 2014 | 745 | 0.180 |
Why?
|
| Isoenzymes | 1 | 2001 | 304 | 0.180 |
Why?
|
| Antirheumatic Agents | 2 | 2021 | 282 | 0.180 |
Why?
|
| Chemokines | 4 | 2012 | 222 | 0.170 |
Why?
|
| Home Childbirth | 1 | 2020 | 5 | 0.170 |
Why?
|
| Doulas | 1 | 2020 | 3 | 0.170 |
Why?
|
| Genetic Association Studies | 4 | 2015 | 361 | 0.170 |
Why?
|
| Carrier Proteins | 1 | 2004 | 732 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 4 | 2003 | 449 | 0.170 |
Why?
|
| Necrosis | 1 | 2021 | 231 | 0.170 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2017 | 30 | 0.170 |
Why?
|
| Microbiota | 3 | 2018 | 720 | 0.170 |
Why?
|
| Farmers | 1 | 2021 | 67 | 0.170 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 2739 | 0.170 |
Why?
|
| Warfare | 1 | 2000 | 63 | 0.170 |
Why?
|
| Keratin-15 | 1 | 2019 | 14 | 0.170 |
Why?
|
| Pregnant Women | 1 | 2021 | 114 | 0.170 |
Why?
|
| Quinazolines | 1 | 2021 | 243 | 0.170 |
Why?
|
| Binding Sites | 3 | 2021 | 1241 | 0.170 |
Why?
|
| Bronchoalveolar Lavage | 3 | 2014 | 89 | 0.170 |
Why?
|
| Molecular Sequence Data | 8 | 2011 | 2819 | 0.170 |
Why?
|
| Cells, Cultured | 9 | 2018 | 4010 | 0.160 |
Why?
|
| Longitudinal Studies | 7 | 2017 | 2715 | 0.160 |
Why?
|
| Reproducibility of Results | 8 | 2018 | 3033 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 864 | 0.160 |
Why?
|
| Spleen | 3 | 2012 | 513 | 0.160 |
Why?
|
| Dilatation | 1 | 2020 | 59 | 0.160 |
Why?
|
| Odds Ratio | 4 | 2018 | 1025 | 0.160 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 605 | 0.160 |
Why?
|
| Interleukin-4 | 2 | 2015 | 213 | 0.160 |
Why?
|
| Colloids | 1 | 2019 | 57 | 0.160 |
Why?
|
| Proteins | 4 | 2015 | 936 | 0.160 |
Why?
|
| Lymphocyte Subsets | 1 | 2019 | 85 | 0.160 |
Why?
|
| Midwifery | 1 | 2020 | 51 | 0.160 |
Why?
|
| Interferon-beta | 2 | 2011 | 87 | 0.160 |
Why?
|
| Hospital Medicine | 1 | 2021 | 91 | 0.160 |
Why?
|
| alpha-Macroglobulins | 1 | 2019 | 24 | 0.160 |
Why?
|
| MicroRNAs | 3 | 2014 | 677 | 0.160 |
Why?
|
| Chromosomes | 3 | 2008 | 101 | 0.160 |
Why?
|
| ERG1 Potassium Channel | 1 | 2018 | 4 | 0.160 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 137 | 0.160 |
Why?
|
| Interleukin-5 Receptor alpha Subunit | 1 | 2018 | 6 | 0.160 |
Why?
|
| Survival Rate | 6 | 2019 | 1875 | 0.160 |
Why?
|
| Expectorants | 1 | 2018 | 23 | 0.160 |
Why?
|
| Exoribonucleases | 1 | 2019 | 43 | 0.160 |
Why?
|
| Gastrointestinal Contents | 1 | 1998 | 7 | 0.160 |
Why?
|
| Colistin | 1 | 2018 | 9 | 0.160 |
Why?
|
| Colitis | 1 | 2021 | 240 | 0.160 |
Why?
|
| Viral Vaccines | 1 | 2020 | 94 | 0.160 |
Why?
|
| Pneumonia, Aspiration | 1 | 1998 | 17 | 0.150 |
Why?
|
| Interleukin-12 | 1 | 1999 | 120 | 0.150 |
Why?
|
| Mucous Membrane | 1 | 2019 | 120 | 0.150 |
Why?
|
| Adipokines | 1 | 2019 | 46 | 0.150 |
Why?
|
| Particulate Matter | 3 | 2009 | 245 | 0.150 |
Why?
|
| Maternal Health Services | 1 | 2020 | 96 | 0.150 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 130 | 0.150 |
Why?
|
| Nasal Lavage Fluid | 2 | 2009 | 14 | 0.150 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2019 | 95 | 0.150 |
Why?
|
| Oligonucleotides | 1 | 1999 | 138 | 0.150 |
Why?
|
| Smoking Cessation | 2 | 2020 | 408 | 0.150 |
Why?
|
| Biological Products | 2 | 2021 | 200 | 0.150 |
Why?
|
| Sri Lanka | 1 | 2018 | 7 | 0.150 |
Why?
|
| Hedgehog Proteins | 3 | 2022 | 187 | 0.150 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 380 | 0.150 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 2 | 2008 | 59 | 0.150 |
Why?
|
| Heterozygote | 6 | 2021 | 267 | 0.150 |
Why?
|
| Lymphocytes | 4 | 2008 | 369 | 0.150 |
Why?
|
| Rhodobacter sphaeroides | 1 | 1998 | 7 | 0.150 |
Why?
|
| Infant, Premature | 1 | 2002 | 539 | 0.150 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 102 | 0.150 |
Why?
|
| RNA Polymerase II | 2 | 2021 | 317 | 0.150 |
Why?
|
| Triamcinolone Acetonide | 1 | 1998 | 27 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 146 | 0.150 |
Why?
|
| Prognosis | 7 | 2019 | 3788 | 0.150 |
Why?
|
| Macrophage Activation | 4 | 2011 | 187 | 0.140 |
Why?
|
| Consensus | 4 | 2021 | 638 | 0.140 |
Why?
|
| Point Mutation | 2 | 2000 | 224 | 0.140 |
Why?
|
| Intestines | 1 | 2021 | 349 | 0.140 |
Why?
|
| Betaine | 1 | 2018 | 72 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2017 | 10 | 0.140 |
Why?
|
| Mass Screening | 2 | 2018 | 1159 | 0.140 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2017 | 46 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 758 | 0.140 |
Why?
|
| Nicotine | 1 | 2020 | 303 | 0.140 |
Why?
|
| Adoptive Transfer | 3 | 2009 | 217 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 571 | 0.140 |
Why?
|
| Dinucleoside Phosphates | 1 | 1997 | 28 | 0.140 |
Why?
|
| Pentoxifylline | 1 | 1997 | 23 | 0.140 |
Why?
|
| Flow Cytometry | 3 | 2013 | 1142 | 0.140 |
Why?
|
| Sex Factors | 7 | 2018 | 1953 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2017 | 131 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2009 | 313 | 0.140 |
Why?
|
| Arrestins | 2 | 2009 | 14 | 0.140 |
Why?
|
| Administration, Intranasal | 1 | 2017 | 82 | 0.140 |
Why?
|
| Bronchoconstrictor Agents | 4 | 2011 | 16 | 0.140 |
Why?
|
| Fear | 1 | 2020 | 325 | 0.140 |
Why?
|
| Vaccination | 2 | 2024 | 1349 | 0.140 |
Why?
|
| Protein Binding | 2 | 2017 | 2106 | 0.140 |
Why?
|
| Blood | 3 | 2008 | 100 | 0.140 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1997 | 85 | 0.140 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2017 | 71 | 0.130 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 343 | 0.130 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 232 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2019 | 634 | 0.130 |
Why?
|
| Cell Adhesion | 3 | 2014 | 445 | 0.130 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 117 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2012 | 940 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 312 | 0.130 |
Why?
|
| Interferon-alpha | 1 | 1997 | 192 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 52 | 0.130 |
Why?
|
| Environmental Pollutants | 2 | 2011 | 142 | 0.130 |
Why?
|
| Gram-Positive Bacteria | 1 | 2016 | 45 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 736 | 0.130 |
Why?
|
| Pulmonary Diffusing Capacity | 7 | 2005 | 74 | 0.130 |
Why?
|
| Incidence | 1 | 2023 | 2635 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 751 | 0.130 |
Why?
|
| Trypanosoma cruzi | 2 | 2015 | 24 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2329 | 0.130 |
Why?
|
| Veterans | 4 | 2004 | 1419 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 201 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2017 | 142 | 0.130 |
Why?
|
| Sus scrofa | 2 | 2021 | 46 | 0.130 |
Why?
|
| Quality of Life | 4 | 2021 | 2693 | 0.130 |
Why?
|
| Carbon Monoxide | 2 | 2012 | 68 | 0.120 |
Why?
|
| Self Care | 1 | 2018 | 368 | 0.120 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2007 | 141 | 0.120 |
Why?
|
| Risk | 3 | 2015 | 856 | 0.120 |
Why?
|
| Hydrocortisone | 1 | 1998 | 304 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2008 | 113 | 0.120 |
Why?
|
| Cell Division | 4 | 2004 | 779 | 0.120 |
Why?
|
| Radiography | 5 | 2005 | 865 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1573 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 267 | 0.120 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 1995 | 37 | 0.120 |
Why?
|
| Trachea | 3 | 2009 | 221 | 0.120 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 6 | 0.120 |
Why?
|
| Hospitals | 1 | 2020 | 632 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 156 | 0.120 |
Why?
|
| Antigens, Dermatophagoides | 2 | 2014 | 10 | 0.120 |
Why?
|
| Communicable Diseases | 1 | 2017 | 144 | 0.120 |
Why?
|
| Proteomics | 4 | 2025 | 1010 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2009 | 336 | 0.120 |
Why?
|
| Global Health | 1 | 2018 | 328 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 326 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1417 | 0.120 |
Why?
|
| Research | 4 | 2005 | 410 | 0.120 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 26 | 0.120 |
Why?
|
| Acetylcysteine | 1 | 2015 | 144 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2008 | 634 | 0.120 |
Why?
|
| Mice, 129 Strain | 2 | 2012 | 80 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 2 | 2013 | 402 | 0.120 |
Why?
|
| NF-kappa B | 3 | 2014 | 652 | 0.120 |
Why?
|
| Computational Biology | 3 | 2009 | 598 | 0.110 |
Why?
|
| Air Pollution | 1 | 2017 | 214 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1209 | 0.110 |
Why?
|
| Gene-Environment Interaction | 2 | 2014 | 185 | 0.110 |
Why?
|
| Antigens, Protozoan | 2 | 2012 | 22 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 421 | 0.110 |
Why?
|
| Isoleucine | 1 | 2014 | 14 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2007 | 396 | 0.110 |
Why?
|
| Pilot Projects | 2 | 2020 | 1567 | 0.110 |
Why?
|
| Threonine | 1 | 2014 | 44 | 0.110 |
Why?
|
| Interleukins | 1 | 1996 | 245 | 0.110 |
Why?
|
| Proto-Oncogenes | 1 | 1994 | 29 | 0.110 |
Why?
|
| Ribonucleoprotein, U5 Small Nuclear | 1 | 2013 | 11 | 0.110 |
Why?
|
| Cluster Analysis | 4 | 2022 | 478 | 0.110 |
Why?
|
| Peptide Elongation Factors | 1 | 2013 | 15 | 0.110 |
Why?
|
| Algorithms | 2 | 2019 | 1621 | 0.110 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2013 | 9 | 0.110 |
Why?
|
| beta-Lactamases | 2 | 2005 | 34 | 0.110 |
Why?
|
| Homeostasis | 3 | 2009 | 605 | 0.110 |
Why?
|
| Genes, ras | 1 | 1994 | 98 | 0.110 |
Why?
|
| Membrane Proteins | 3 | 2016 | 1109 | 0.110 |
Why?
|
| Prolactinoma | 1 | 2013 | 12 | 0.110 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2013 | 62 | 0.110 |
Why?
|
| Sensitivity and Specificity | 6 | 2011 | 1825 | 0.110 |
Why?
|
| Vehicle Emissions | 1 | 2013 | 56 | 0.110 |
Why?
|
| HLA-A Antigens | 1 | 1993 | 53 | 0.110 |
Why?
|
| Saskatchewan | 3 | 2021 | 7 | 0.110 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2013 | 23 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 1998 | 575 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 201 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 4 | 2024 | 167 | 0.110 |
Why?
|
| Myocardial Contraction | 1 | 2015 | 331 | 0.110 |
Why?
|
| Apoptosis | 3 | 2023 | 2438 | 0.110 |
Why?
|
| Agammaglobulinemia | 1 | 2013 | 33 | 0.110 |
Why?
|
| Chromosomes, Human | 1 | 2013 | 41 | 0.100 |
Why?
|
| HLA-B Antigens | 1 | 1993 | 62 | 0.100 |
Why?
|
| Iowa | 4 | 2004 | 24 | 0.100 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 1994 | 79 | 0.100 |
Why?
|
| Coal Ash | 2 | 2004 | 4 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 737 | 0.100 |
Why?
|
| Physical Exertion | 1 | 1994 | 212 | 0.100 |
Why?
|
| Pulmonary Surfactants | 3 | 2016 | 106 | 0.100 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 44 | 0.100 |
Why?
|
| Biology | 2 | 2023 | 83 | 0.100 |
Why?
|
| Child, Preschool | 6 | 2022 | 10450 | 0.100 |
Why?
|
| HLA-DQ Antigens | 1 | 1993 | 179 | 0.100 |
Why?
|
| Solubility | 2 | 2017 | 229 | 0.100 |
Why?
|
| H-2 Antigens | 1 | 2012 | 115 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 1993 | 225 | 0.100 |
Why?
|
| Bone Marrow | 2 | 2010 | 268 | 0.100 |
Why?
|
| Methotrexate | 3 | 2021 | 250 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 294 | 0.100 |
Why?
|
| Cell Separation | 1 | 2013 | 313 | 0.100 |
Why?
|
| Histamine | 1 | 1992 | 64 | 0.100 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2012 | 57 | 0.100 |
Why?
|
| Aluminum Silicates | 1 | 1991 | 11 | 0.100 |
Why?
|
| Recurrence | 3 | 2021 | 1003 | 0.090 |
Why?
|
| Observer Variation | 1 | 2012 | 315 | 0.090 |
Why?
|
| Hirschsprung Disease | 1 | 2013 | 101 | 0.090 |
Why?
|
| Caspases, Initiator | 1 | 2011 | 18 | 0.090 |
Why?
|
| Sample Size | 2 | 2022 | 115 | 0.090 |
Why?
|
| Pulmonary Ventilation | 3 | 1997 | 76 | 0.090 |
Why?
|
| Europe | 3 | 2022 | 362 | 0.090 |
Why?
|
| Amino Acid Sequence | 4 | 2011 | 2041 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2021 | 591 | 0.090 |
Why?
|
| Bronchitis | 2 | 2002 | 42 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 2013 | 184 | 0.090 |
Why?
|
| Collagen | 2 | 2006 | 429 | 0.090 |
Why?
|
| beta-Lactam Resistance | 1 | 2011 | 5 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 519 | 0.090 |
Why?
|
| Myocarditis | 1 | 2012 | 98 | 0.090 |
Why?
|
| Carbon | 2 | 2004 | 207 | 0.090 |
Why?
|
| Finland | 2 | 2019 | 90 | 0.090 |
Why?
|
| Depression | 2 | 2018 | 1292 | 0.090 |
Why?
|
| Escherichia coli Infections | 1 | 2011 | 106 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 1998 | 513 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 195 | 0.090 |
Why?
|
| Nitric Oxide | 3 | 2014 | 886 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 426 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 173 | 0.090 |
Why?
|
| Accidents, Occupational | 1 | 1990 | 15 | 0.090 |
Why?
|
| Caspases | 1 | 2011 | 242 | 0.090 |
Why?
|
| Haplotypes | 3 | 2021 | 471 | 0.080 |
Why?
|
| Gases | 1 | 1990 | 44 | 0.080 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 264 | 0.080 |
Why?
|
| Serratia marcescens | 1 | 2009 | 13 | 0.080 |
Why?
|
| Paternal Age | 1 | 1989 | 3 | 0.080 |
Why?
|
| Endothelial Cells | 2 | 2023 | 701 | 0.080 |
Why?
|
| Chlorine | 1 | 1990 | 58 | 0.080 |
Why?
|
| Cross Infection | 2 | 2010 | 196 | 0.080 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2010 | 46 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2013 | 400 | 0.080 |
Why?
|
| Chemokine CXCL1 | 1 | 2009 | 73 | 0.080 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 2 | 2025 | 35 | 0.080 |
Why?
|
| Family | 2 | 2025 | 648 | 0.080 |
Why?
|
| Plethysmography | 2 | 2004 | 109 | 0.080 |
Why?
|
| Growth Substances | 1 | 1989 | 151 | 0.080 |
Why?
|
| Metallothionein | 1 | 2009 | 24 | 0.080 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2012 | 136 | 0.080 |
Why?
|
| Pyroglyphidae | 2 | 2023 | 17 | 0.080 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 5068 | 0.080 |
Why?
|
| Iceland | 2 | 2019 | 10 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 182 | 0.080 |
Why?
|
| Genome | 1 | 2011 | 277 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 269 | 0.080 |
Why?
|
| Mice, Inbred NZB | 1 | 2008 | 15 | 0.080 |
Why?
|
| Mice, Inbred AKR | 1 | 2008 | 34 | 0.080 |
Why?
|
| Mice, Inbred A | 1 | 2008 | 47 | 0.080 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2009 | 113 | 0.080 |
Why?
|
| Mycology | 1 | 2008 | 3 | 0.080 |
Why?
|
| Gene Library | 1 | 2008 | 116 | 0.080 |
Why?
|
| Fungemia | 1 | 2008 | 4 | 0.080 |
Why?
|
| Nitric Oxide Synthase | 2 | 2006 | 232 | 0.080 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2008 | 38 | 0.080 |
Why?
|
| Procollagen | 1 | 2008 | 21 | 0.080 |
Why?
|
| Aspergillus fumigatus | 1 | 2008 | 23 | 0.080 |
Why?
|
| Bronchoscopy | 3 | 2014 | 208 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2013 | 828 | 0.070 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2008 | 150 | 0.070 |
Why?
|
| Candida | 1 | 2008 | 35 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 138 | 0.070 |
Why?
|
| Candidiasis | 1 | 2008 | 53 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 1943 | 0.070 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2008 | 31 | 0.070 |
Why?
|
| Paint | 1 | 1988 | 7 | 0.070 |
Why?
|
| Adenoviridae | 2 | 2006 | 190 | 0.070 |
Why?
|
| Feces | 1 | 2011 | 437 | 0.070 |
Why?
|
| Bacteria | 1 | 2014 | 811 | 0.070 |
Why?
|
| Brachiocephalic Veins | 1 | 2007 | 4 | 0.070 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 74 | 0.070 |
Why?
|
| Immune Complex Diseases | 1 | 2007 | 7 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 120 | 0.070 |
Why?
|
| Chemokine CCL5 | 1 | 2007 | 42 | 0.070 |
Why?
|
| Chemotactic Factors | 2 | 1998 | 54 | 0.070 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2007 | 16 | 0.070 |
Why?
|
| Protein Interaction Mapping | 1 | 2008 | 109 | 0.070 |
Why?
|
| Software | 1 | 2012 | 610 | 0.070 |
Why?
|
| Liver | 3 | 2012 | 1833 | 0.070 |
Why?
|
| Recombination, Genetic | 2 | 2005 | 189 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 1997 | 1063 | 0.070 |
Why?
|
| Azacitidine | 1 | 2008 | 140 | 0.070 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2007 | 39 | 0.070 |
Why?
|
| Dinoprostone | 2 | 2001 | 187 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 1284 | 0.070 |
Why?
|
| Lung Compliance | 1 | 2007 | 45 | 0.070 |
Why?
|
| Placebos | 2 | 1998 | 201 | 0.070 |
Why?
|
| Cytokinesis | 1 | 2007 | 48 | 0.070 |
Why?
|
| Intestinal Mucosa | 2 | 2024 | 579 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 1994 | 1185 | 0.070 |
Why?
|
| Neutrophil Activation | 1 | 2007 | 77 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 930 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2018 | 749 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 1994 | 889 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 1998 | 269 | 0.070 |
Why?
|
| Arm | 1 | 2007 | 110 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 1363 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2012 | 372 | 0.070 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2007 | 80 | 0.070 |
Why?
|
| Crosses, Genetic | 2 | 2011 | 142 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 118 | 0.070 |
Why?
|
| Aerosols | 2 | 2001 | 172 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 68 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 231 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2007 | 291 | 0.070 |
Why?
|
| Lymphokines | 1 | 2006 | 115 | 0.070 |
Why?
|
| Monocytes | 1 | 1989 | 543 | 0.070 |
Why?
|
| Chimera | 1 | 2006 | 59 | 0.070 |
Why?
|
| Chemokine CXCL12 | 1 | 2006 | 77 | 0.070 |
Why?
|
| Cell Count | 2 | 1998 | 314 | 0.070 |
Why?
|
| Receptors, CXCR4 | 1 | 2006 | 82 | 0.070 |
Why?
|
| Nitrites | 1 | 2006 | 81 | 0.060 |
Why?
|
| Ear, Middle | 2 | 2018 | 91 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 346 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2007 | 206 | 0.060 |
Why?
|
| Response Elements | 1 | 2006 | 89 | 0.060 |
Why?
|
| Organizational Policy | 1 | 2006 | 76 | 0.060 |
Why?
|
| Postal Service | 2 | 1996 | 32 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2007 | 799 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2015 | 2266 | 0.060 |
Why?
|
| Models, Biological | 3 | 2013 | 1695 | 0.060 |
Why?
|
| Agar | 2 | 2018 | 11 | 0.060 |
Why?
|
| Genes, Recessive | 1 | 2005 | 77 | 0.060 |
Why?
|
| Wnt Proteins | 1 | 2006 | 126 | 0.060 |
Why?
|
| S-Nitrosothiols | 1 | 2005 | 4 | 0.060 |
Why?
|
| S-Nitrosoglutathione | 1 | 2005 | 7 | 0.060 |
Why?
|
| Glutathione Reductase | 1 | 2005 | 23 | 0.060 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2005 | 111 | 0.060 |
Why?
|
| Learning | 1 | 1989 | 396 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2020 | 562 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 774 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2009 | 1687 | 0.060 |
Why?
|
| Transplantation, Heterotopic | 1 | 2005 | 17 | 0.060 |
Why?
|
| Oxidative Stress | 2 | 2009 | 1192 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 811 | 0.060 |
Why?
|
| Body Temperature | 1 | 2006 | 216 | 0.060 |
Why?
|
| Rural Population | 1 | 2009 | 512 | 0.060 |
Why?
|
| Chimerism | 1 | 2004 | 29 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2006 | 311 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 2023 | 522 | 0.060 |
Why?
|
| Population Surveillance | 2 | 2000 | 428 | 0.060 |
Why?
|
| T-Lymphocytes | 3 | 2009 | 1924 | 0.060 |
Why?
|
| Amino Acid Substitution | 2 | 2005 | 281 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2004 | 832 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2003 | 292 | 0.060 |
Why?
|
| Interferons | 1 | 2006 | 192 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 151 | 0.060 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2005 | 54 | 0.060 |
Why?
|
| DNA Primers | 2 | 1997 | 510 | 0.060 |
Why?
|
| I-kappa B Kinase | 1 | 2004 | 53 | 0.060 |
Why?
|
| Evolution, Molecular | 1 | 2008 | 467 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2016 | 257 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2004 | 55 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2005 | 113 | 0.060 |
Why?
|
| Reference Values | 2 | 2000 | 780 | 0.060 |
Why?
|
| Peroxidase | 1 | 2004 | 169 | 0.060 |
Why?
|
| Sputum | 2 | 1997 | 304 | 0.060 |
Why?
|
| Superoxide Dismutase | 1 | 2006 | 328 | 0.060 |
Why?
|
| K562 Cells | 1 | 2024 | 82 | 0.060 |
Why?
|
| Fever | 1 | 2006 | 301 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 2004 | 104 | 0.060 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2004 | 30 | 0.060 |
Why?
|
| Lakes | 1 | 2024 | 30 | 0.060 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 162 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 308 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2005 | 192 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 818 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 64 | 0.050 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2003 | 6 | 0.050 |
Why?
|
| DNA, Protozoan | 1 | 2003 | 26 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2007 | 420 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 1098 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2004 | 163 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2023 | 30 | 0.050 |
Why?
|
| Bronchitis, Chronic | 1 | 2003 | 19 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 110 | 0.050 |
Why?
|
| Demography | 1 | 2024 | 277 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 479 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 83 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2003 | 76 | 0.050 |
Why?
|
| Petroleum | 1 | 2002 | 8 | 0.050 |
Why?
|
| DNA Damage | 1 | 2005 | 364 | 0.050 |
Why?
|
| Interleukin-5 | 1 | 2003 | 45 | 0.050 |
Why?
|
| CD18 Antigens | 1 | 2002 | 26 | 0.050 |
Why?
|
| Teichoic Acids | 1 | 2002 | 13 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 2 | 2003 | 836 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2002 | 17 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2018 | 687 | 0.050 |
Why?
|
| Geographic Information Systems | 1 | 2002 | 40 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1493 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2024 | 288 | 0.050 |
Why?
|
| Serotonin | 1 | 2005 | 318 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 2475 | 0.050 |
Why?
|
| Proteolipids | 1 | 2002 | 30 | 0.050 |
Why?
|
| Carcinogens | 1 | 2002 | 110 | 0.050 |
Why?
|
| Pulmonary Medicine | 1 | 2003 | 80 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 182 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2002 | 65 | 0.050 |
Why?
|
| Combat Disorders | 1 | 2002 | 37 | 0.050 |
Why?
|
| Plethysmography, Whole Body | 1 | 2001 | 5 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 22 | 0.050 |
Why?
|
| Cutaneous Fistula | 1 | 2021 | 13 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 535 | 0.050 |
Why?
|
| Intestinal Fistula | 1 | 2021 | 15 | 0.050 |
Why?
|
| Leukotriene B4 | 1 | 2001 | 40 | 0.050 |
Why?
|
| Cyclooxygenase 1 | 1 | 2001 | 26 | 0.050 |
Why?
|
| Intestinal Polyps | 1 | 2021 | 17 | 0.050 |
Why?
|
| Causality | 1 | 2002 | 115 | 0.050 |
Why?
|
| Myofibroblasts | 1 | 2023 | 128 | 0.050 |
Why?
|
| Wound Healing | 1 | 2004 | 311 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 235 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 104 | 0.050 |
Why?
|
| Heart Rate | 1 | 2006 | 808 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 153 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2021 | 38 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2021 | 15 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 1999 | 193 | 0.050 |
Why?
|
| Anatomic Landmarks | 1 | 2021 | 28 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2001 | 150 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 48 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 39 | 0.050 |
Why?
|
| Epilepsies, Partial | 1 | 2001 | 46 | 0.050 |
Why?
|
| Lac Operon | 1 | 2001 | 45 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2021 | 29 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2005 | 347 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2021 | 55 | 0.040 |
Why?
|
| alpha Karyopherins | 1 | 2020 | 11 | 0.040 |
Why?
|
| Staphylococcus aureus | 2 | 2016 | 431 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2001 | 172 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 53 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2004 | 425 | 0.040 |
Why?
|
| Tripartite Motif Proteins | 1 | 2020 | 31 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2004 | 347 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2002 | 207 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 156 | 0.040 |
Why?
|
| Population Density | 1 | 2021 | 91 | 0.040 |
Why?
|
| Middle East | 1 | 2000 | 11 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2021 | 150 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 98 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 29 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 54 | 0.040 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2001 | 179 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 220 | 0.040 |
Why?
|
| Linear Models | 2 | 2015 | 816 | 0.040 |
Why?
|
| Telephone | 1 | 2021 | 169 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 181 | 0.040 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Bupropion | 1 | 2020 | 41 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 601 | 0.040 |
Why?
|
| beta Karyopherins | 1 | 2019 | 6 | 0.040 |
Why?
|
| Varenicline | 1 | 2020 | 26 | 0.040 |
Why?
|
| Faculty | 1 | 2021 | 137 | 0.040 |
Why?
|
| Trichinellosis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Trichinella spiralis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Cross Protection | 1 | 2019 | 4 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2019 | 18 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 603 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2007 | 2347 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 179 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2013 | 95 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 261 | 0.040 |
Why?
|
| Philippines | 1 | 2019 | 49 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2017 | 427 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2000 | 285 | 0.040 |
Why?
|
| Pakistan | 1 | 2019 | 75 | 0.040 |
Why?
|
| Biopsy | 4 | 2012 | 1086 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 574 | 0.040 |
Why?
|
| Transfection | 1 | 2001 | 896 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 93 | 0.040 |
Why?
|
| Gestational Age | 1 | 2002 | 868 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 190 | 0.040 |
Why?
|
| Mitochondria | 1 | 2005 | 854 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 170 | 0.040 |
Why?
|
| Rural Health | 1 | 1999 | 70 | 0.040 |
Why?
|
| Virus Physiological Phenomena | 1 | 2018 | 6 | 0.040 |
Why?
|
| Gastric Acidity Determination | 1 | 1998 | 7 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 252 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 622 | 0.040 |
Why?
|
| Stem Cells | 1 | 2023 | 579 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2006 | 1735 | 0.040 |
Why?
|
| Actins | 1 | 2001 | 402 | 0.040 |
Why?
|
| Esophageal Diseases | 1 | 1998 | 27 | 0.040 |
Why?
|
| Homozygote | 2 | 2009 | 193 | 0.040 |
Why?
|
| Anesthesia, General | 1 | 1998 | 50 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2002 | 724 | 0.040 |
Why?
|
| COS Cells | 1 | 2018 | 184 | 0.040 |
Why?
|
| Stomach | 1 | 1998 | 109 | 0.040 |
Why?
|
| Environmental Pollution | 1 | 2018 | 18 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 656 | 0.040 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2018 | 58 | 0.040 |
Why?
|
| Premedication | 1 | 1998 | 40 | 0.040 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2017 | 5 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 872 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 28 | 0.040 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2017 | 22 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2021 | 266 | 0.040 |
Why?
|
| Conscious Sedation | 1 | 1998 | 84 | 0.040 |
Why?
|
| Military Personnel | 2 | 2004 | 518 | 0.040 |
Why?
|
| Maternal Health | 1 | 2018 | 46 | 0.040 |
Why?
|
| Schools | 1 | 2021 | 439 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 2 | 1995 | 117 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2017 | 91 | 0.030 |
Why?
|
| beta-Arrestin 2 | 2 | 2009 | 6 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 380 | 0.030 |
Why?
|
| Chromatin | 1 | 2021 | 478 | 0.030 |
Why?
|
| beta-Arrestins | 2 | 2009 | 14 | 0.030 |
Why?
|
| Leadership | 1 | 2021 | 357 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 385 | 0.030 |
Why?
|
| Penicillamine | 1 | 1996 | 23 | 0.030 |
Why?
|
| Workflow | 1 | 2018 | 155 | 0.030 |
Why?
|
| Fasting | 1 | 1998 | 264 | 0.030 |
Why?
|
| Carrier State | 1 | 1997 | 60 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1997 | 228 | 0.030 |
Why?
|
| Folic Acid | 1 | 2018 | 184 | 0.030 |
Why?
|
| Polymyxin B | 1 | 1996 | 19 | 0.030 |
Why?
|
| Chemical Fractionation | 1 | 1996 | 29 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2016 | 89 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 1998 | 197 | 0.030 |
Why?
|
| Text Messaging | 1 | 2018 | 149 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2016 | 73 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 367 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 63 | 0.030 |
Why?
|
| Forecasting | 1 | 2018 | 358 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 580 | 0.030 |
Why?
|
| Child Health | 1 | 2018 | 146 | 0.030 |
Why?
|
| Microspheres | 1 | 1996 | 124 | 0.030 |
Why?
|
| ADAMTS9 Protein | 1 | 2015 | 6 | 0.030 |
Why?
|
| Serpin E2 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2015 | 8 | 0.030 |
Why?
|
| ADAMTS4 Protein | 1 | 2015 | 15 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 53 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 1359 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3383 | 0.030 |
Why?
|
| Emphysema | 1 | 2016 | 95 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2010 | 719 | 0.030 |
Why?
|
| Stents | 1 | 2020 | 504 | 0.030 |
Why?
|
| Serpins | 1 | 2015 | 31 | 0.030 |
Why?
|
| Gold | 1 | 1996 | 118 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2015 | 58 | 0.030 |
Why?
|
| Kinetics | 1 | 1999 | 1617 | 0.030 |
Why?
|
| Aspergillus oryzae | 1 | 2015 | 4 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 1997 | 213 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 28 | 0.030 |
Why?
|
| Dermatophagoides pteronyssinus | 1 | 2014 | 3 | 0.030 |
Why?
|
| Residual Volume | 2 | 1995 | 6 | 0.030 |
Why?
|
| Blood Cells | 1 | 2014 | 38 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2007 | 343 | 0.030 |
Why?
|
| Agriculture | 1 | 1995 | 92 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 1995 | 121 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 72 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2014 | 67 | 0.030 |
Why?
|
| Respiratory Dead Space | 1 | 1994 | 2 | 0.030 |
Why?
|
| Genetics | 1 | 2014 | 25 | 0.030 |
Why?
|
| Cough | 1 | 1995 | 116 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 190 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1996 | 179 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 1994 | 25 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1994 | 82 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2006 | 2496 | 0.030 |
Why?
|
| Mass Chest X-Ray | 1 | 1994 | 4 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 32 | 0.030 |
Why?
|
| Random Allocation | 1 | 1995 | 346 | 0.030 |
Why?
|
| Galactorrhea | 1 | 2013 | 1 | 0.030 |
Why?
|
| HLA-B44 Antigen | 1 | 1993 | 2 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2013 | 6 | 0.030 |
Why?
|
| HLA-DRB4 Chains | 1 | 1993 | 6 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 1993 | 37 | 0.030 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 51 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1994 | 159 | 0.030 |
Why?
|
| Remission Induction | 1 | 1994 | 271 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2011 | 846 | 0.030 |
Why?
|
| Equipment Design | 1 | 1995 | 518 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2013 | 107 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1423 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1994 | 304 | 0.030 |
Why?
|
| APACHE | 1 | 2013 | 62 | 0.030 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2012 | 12 | 0.030 |
Why?
|
| Urine | 1 | 1993 | 54 | 0.030 |
Why?
|
| Fibronectins | 1 | 1993 | 120 | 0.030 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2012 | 30 | 0.030 |
Why?
|
| DNA Probes | 1 | 2012 | 61 | 0.030 |
Why?
|
| Programming Languages | 1 | 2012 | 22 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1994 | 254 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 568 | 0.030 |
Why?
|
| Brain | 1 | 2005 | 2628 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 245 | 0.030 |
Why?
|
| Multigene Family | 1 | 2013 | 198 | 0.020 |
Why?
|
| Diarrhea | 1 | 2013 | 177 | 0.020 |
Why?
|
| Latin America | 1 | 2012 | 86 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 2012 | 46 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 165 | 0.020 |
Why?
|
| Tobacco Products | 1 | 2013 | 111 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 148 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 1999 | 897 | 0.020 |
Why?
|
| Functional Residual Capacity | 1 | 1991 | 8 | 0.020 |
Why?
|
| Education | 1 | 2012 | 100 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2013 | 218 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2012 | 171 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 1994 | 336 | 0.020 |
Why?
|
| Arthropod Proteins | 1 | 2011 | 4 | 0.020 |
Why?
|
| Mast Cells | 1 | 1992 | 142 | 0.020 |
Why?
|
| Poly I-C | 1 | 2011 | 62 | 0.020 |
Why?
|
| Antigens | 1 | 2013 | 353 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1993 | 150 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2011 | 67 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2012 | 465 | 0.020 |
Why?
|
| Greece | 1 | 2010 | 7 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 451 | 0.020 |
Why?
|
| Metallurgy | 1 | 1990 | 9 | 0.020 |
Why?
|
| Listeriosis | 1 | 2011 | 67 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 330 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 99 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 1994 | 1293 | 0.020 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2009 | 15 | 0.020 |
Why?
|
| Listeria monocytogenes | 1 | 2011 | 123 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 324 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 188 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 206 | 0.020 |
Why?
|
| Biological Evolution | 1 | 2012 | 426 | 0.020 |
Why?
|
| Resuscitation | 1 | 1991 | 240 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 303 | 0.020 |
Why?
|
| Thrombosis | 1 | 2012 | 323 | 0.020 |
Why?
|
| Abortion, Habitual | 1 | 1988 | 4 | 0.020 |
Why?
|
| Host vs Graft Reaction | 1 | 1988 | 2 | 0.020 |
Why?
|
| Helium | 1 | 2007 | 6 | 0.020 |
Why?
|
| Calcium Phosphates | 1 | 2007 | 22 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 283 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2009 | 228 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 352 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 82 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 492 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2009 | 308 | 0.020 |
Why?
|
| Rats | 2 | 2006 | 5173 | 0.020 |
Why?
|
| Infertility, Female | 1 | 1988 | 105 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2007 | 158 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 411 | 0.020 |
Why?
|
| Antibodies | 1 | 1988 | 391 | 0.020 |
Why?
|
| Imines | 1 | 2005 | 8 | 0.020 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2005 | 16 | 0.020 |
Why?
|
| Psychometrics | 1 | 1989 | 685 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 463 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2005 | 27 | 0.020 |
Why?
|
| Cephalosporin Resistance | 1 | 2005 | 1 | 0.020 |
Why?
|
| Cefotaxime | 1 | 2005 | 3 | 0.020 |
Why?
|
| Ceftazidime | 1 | 2005 | 5 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2005 | 41 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2005 | 107 | 0.010 |
Why?
|
| Histidine | 1 | 2005 | 58 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2024 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2005 | 129 | 0.010 |
Why?
|
| Laboratories | 1 | 2005 | 109 | 0.010 |
Why?
|
| Aging | 1 | 2014 | 1771 | 0.010 |
Why?
|
| Pseudogenes | 1 | 2003 | 18 | 0.010 |
Why?
|
| Genes, Protozoan | 1 | 2003 | 11 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 145 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 2005 | 245 | 0.010 |
Why?
|
| Gene Duplication | 1 | 2003 | 68 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 911 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 259 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 393 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2003 | 101 | 0.010 |
Why?
|
| Kuwait | 1 | 2002 | 1 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2003 | 138 | 0.010 |
Why?
|
| Israel | 1 | 2003 | 47 | 0.010 |
Why?
|
| Microbiological Techniques | 1 | 2003 | 30 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2002 | 77 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2003 | 130 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 75 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2003 | 44 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 233 | 0.010 |
Why?
|
| Microelectrodes | 1 | 2001 | 42 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 2001 | 63 | 0.010 |
Why?
|
| Fires | 1 | 2002 | 88 | 0.010 |
Why?
|
| Lymphocyte Antigen 96 | 1 | 2001 | 24 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 1180 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 150 | 0.010 |
Why?
|
| Internet | 1 | 2005 | 620 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 275 | 0.010 |
Why?
|
| Clone Cells | 1 | 2001 | 255 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2001 | 218 | 0.010 |
Why?
|
| Acoustic Stimulation | 1 | 2001 | 325 | 0.010 |
Why?
|
| Reaction Time | 1 | 2001 | 409 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 722 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 2004 | 372 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2001 | 396 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 1546 | 0.010 |
Why?
|
| Attention | 1 | 2001 | 437 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2001 | 571 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 1997 | 43 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 1048 | 0.010 |
Why?
|
| Organ Size | 1 | 1997 | 441 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2002 | 719 | 0.010 |
Why?
|
| Proteus | 1 | 1993 | 6 | 0.010 |
Why?
|
| Pseudomonas | 1 | 1993 | 28 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1993 | 116 | 0.010 |
Why?
|
| Klebsiella pneumoniae | 1 | 1993 | 41 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2004 | 5376 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1993 | 759 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 1271 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1993 | 1013 | 0.010 |
Why?
|